Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a nationwide cohort study

被引：0
|
作者：
Funck, K. L. [1 ]
Bjerg, L. [1 ]
Isaksen, A. A. [1 ]
Sandbaek, A. [1 ]
Grove, E. L. [2 ]
机构：
[1] Aarhus Univ Hosp, Steno Diabet Ctr Aarhus, Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Cardiol, Aarhus N, Denmark
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
336
引用
下载
收藏
页码：S176 / S176
页数：1
相关论文
共 50 条
  • [1] Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
    Funck, Kristian Lokke
    Bjerg, Lasse
    Isaksen, Anders Aasted
    Sandbaek, Annelli
    Grove, Erik Lerkevang
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [2] Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
    Kristian Løkke Funck
    Lasse Bjerg
    Anders Aasted Isaksen
    Annelli Sandbæk
    Erik Lerkevang Grove
    Cardiovascular Diabetology, 21
  • [3] Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
    Funck, Kristian L.
    Knudsen, Jakob S.
    Hansen, Troels K.
    Thomsen, Reimar W.
    Grove, Erik L.
    DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 520 - 529
  • [4] Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
    Ferrannini, Ele
    DeFronzo, Ralph A.
    EUROPEAN HEART JOURNAL, 2015, 36 (34) : 2288 - U19
  • [5] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) : 1267 - 1271
  • [6] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Kalyani, Rita R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1248 - 1260
  • [7] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Donnelly, Peter E.
    Winch, Denis E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07): : 670 - 671
  • [8] Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Inzucchi, Silvio E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 137 - +
  • [9] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update
    Tomlinson, Brian
    Chan, Paul
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 175 - 179
  • [10] Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    Holman, Rury R.
    Sourij, Harald
    Califf, Robert M.
    LANCET, 2014, 383 (9933): : 2008 - 2017
12345